Influenza vaccine effectiveness in Portugal: season 2015/2016 report

This report was prepared as part of the Project “Monitoring Influenza vaccine effectiveness during influenza seasons and pandemics in the European Union” and describes the results obtained in Portugal under the Protocol Agreement celebrated between EpiConcept SARL, Paris and National Health Institute Dr. Ricardo Jorge, Lisbon. Data and activities related to the individuals 65 years and more were funded by European Union’s Horizon 2020 research and innovation programme under grant agreement no 634446.

Combining multispecies home range and distribution models aids assessment of MPA effectiveness

Marine protected areas (MPAs) are today's most important tools for the spatial management and conservation of marine species. Yet, the true protection that they provide to individual fish is unknown, leading to uncertainty associated with MPA effectiveness. In this study, conducted in a recently established coastal MPA in Portugal, we combined the results of individual home range estimation and population distribution models for 3 species of commercial importance and contrasting life histories to infer (1) the size of suitable areas where they would be fully protected and (2) the vulnerability to fishing mortality of each species. Results show that the relationship between MPA size and effective protection is strongly modulated by both the species' home range and the distribution of suitable habitat inside and outside the MPA. This approach provides a better insight into the true potential of MPAs in effectively protecting marine species, since it can reveal the size and location of the areas where protection is most effective and a clear, quantitative estimation of the vulnerability to fishing throughout an entire MPA.

Reducing the global burden of depression : population level analysis of intervention cost-effectiveness in 14 world regions

International evidence on the cost and effects of interventions for reducing the global burden of depression remain scarce. Aims: To estimate the population-level cost-effectiveness of evidence-based depression interventions and their contribution towards reducing current burden. Method: Primary-care-based depression interventions were modelled at the level of whole populations in 14 epidemiological subregions of the world. Total population-level costs (in international dollars or I$) and effectiveness (disability adjusted life years (DALYs) averted) were combined to form average and incremental cost-effectiveness ratios. Results: Evaluated interventions have the potential to reduce the current burden of depression by 10–30%. Pharmacotherapy with older antidepressant drugs, with or without proactive collaborative care, are currently more cost-effective strategies than those using newer antidepressants, particularly in lower-income subregions. Conclusions: Even in resource-poor regions, each DALYaverted by efficient depression treatments in primary care costs less than 1 year of average per capita income, making such interventions a cost-effective use of health resources. However, current levels of burden can only be reduced significantlyif there is a substantialincrease substantial increase intreatment coverage.